Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

malignant conjunctival melanoma News | Kisho

Kisho

Not rare diseases news,
news about your rare disease.

Earlier

A case report highlights cytokine release syndrome triggered by the combination therapy of nivolumab and ipilimumab in a patient with lower palpebral conjunctival melanoma. This finding contributes to the understanding of adverse effects associated with immunotherapy in rare melanoma cases.

A study published on PubMed details the clinicopathological profile of conjunctival melanoma at a referral ophthalmology center in Peru. This research contributes to the understanding of this rare ocular malignancy, although specific findings and implications were not highlighted.

Not rare diseases news,news about your rare disease.

Earlier

A case report highlights cytokine release syndrome triggered by the combination therapy of nivolumab and ipilimumab in a patient with lower palpebral conjunctival melanoma. This finding contributes to the understanding of adverse effects associated with immunotherapy in rare melanoma cases.

A study published on PubMed details the clinicopathological profile of conjunctival melanoma at a referral ophthalmology center in Peru. This research contributes to the understanding of this rare ocular malignancy, although specific findings and implications were not highlighted.

Not rare diseases news,
news about your rare disease.